Multiple Myeloma Hub
Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
Jan 14, 2022
Experts Jacob Laubach and Peter Voorhees discuss the impact of Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma. They highlight findings from the GRIFFIN and CASSIOPEIA trials, showing enhanced response rates, minimal residual disease negativity, and improved progression-free survival. The podcast explores the benefits of incorporating Daratumumab into treatment regimens and its role in enhancing overall outcomes for multiple myeloma patients.
13:24
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- DEROTUMAMAB maintenance post-transplant improves depth of response and progression free survival.
- Incorporating DEROTUMAMAB into therapy components leads to better outcomes and enhanced response rates.
Deep dives
Results of Griffin trial after 24 months of maintenance therapy
The Griffin trial was a randomized phase two clinical trial for transplant eligible patients with newly diagnosed multiple myeloma. Patients received either standard RVD induction therapy or RVD plus DEROTUMAM. Key findings after 24 months of maintenance therapy showed that the stringent complete response rate improved with DEROTUMAM maintenance. MRT negativity rates also increased with longer maintenance therapy periods, demonstrating 64% MRT negativity with DEROTUMAM and LENELITIMIDE after two years.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
